미국의 법의학 유전체학 시장 규모, 점유율, 동향 분석 리포트 : 제품별, 방법별, 용도별, 부문별 예측(2025-2033년)

U.S. Forensic Genomics Market Size & Trends:

The U.S. forensic genomics market size was estimated at USD 256.5 million in 2024 and is projected to reach USD 941.0 million by 2033, expanding at a CAGR of 15.65% from 2025 to 2033. This growth is driven by advancements in genomic technologies, increasing adoption of forensic DNA analysis in criminal investigations, and rising government funding for forensic research and infrastructure. Moreover, the growing need for accurate and rapid identification methods in law enforcement and legal proceedings will fuel market expansion throughout the forecast period.

Increasing Crime Rates and Complexity of Investigations

Rising incidence of criminal activity, particularly violent crimes, sexual assaults, and homicides, is one of the primary drivers of the growth in the forensic genomics market. As the volume and complexity of criminal cases increases, there is a greater need for advanced tools to provide accurate and reliable evidence. Forensic genomics enables law enforcement agencies to analyze biological samples at a highly detailed genetic level, offering superior accuracy in suspect identification and victim profiling compared to traditional forensic methods.

Moreover, the growing number of unresolved and cold cases has prompted agencies to revisit archived evidence using modern genomic techniques, leading to breakthroughs and case resolutions. The demand for rapid turnaround in investigations and pressure to minimize wrongful convictions further underscores the importance of forensic genomics in the modern criminal justice system. These factors collectively contribute to sustained and increasing demand for genomic solutions in forensic applications across the U.S.

U.S. Forensic Genomics Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the U.S. forensic genomics market report based on product, method, and application:

• U.S. Forensic Genomics Product Outlook (Revenue, USD Million, 2021 - 2033)
• Analyzers & Sequencers
• Software
• Kits & Consumables
• U.S. Forensic Genomics Method Outlook (Revenue, USD Million, 2021 - 2033)
• Capillary Electrophoresis
• Next-generation Sequencing
• PCR Amplification
• Others
• U.S. Forensic Genomics Application Outlook (Revenue, USD Million, 2021 - 2033)
• Criminal Testing
• Paternity & Familial Testing
• Others

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Product Segment
  • 1.2.2. Method Segment
  • 1.2.3. Application Segment
• 1.3. Information Analysis
  • 1.3.1. Market Formulation & Data Visualization
• 1.4. Data Validation & Publishing
• 1.5. Information Procurement
  • 1.5.1. Primary Research
• 1.6. Information or Data Analysis
• 1.7. Market Formulation & Validation
• 1.8. Market Model
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Trends and Outlook
• 3.3. Market Dynamics
  • 3.3.1. Market Driver Analysis
    • 3.3.1.1. Rising government funds and initiatives for forensic programs
    • 3.3.1.2. Increasing crime rates
    • 3.3.1.3. Technological advancements in paternity & familial testing
  • 3.3.2. Market Restraint Analysis
    • 3.3.2.1. High cost of equipment
• 3.4. Industry Analysis Tools
  • 3.4.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
  • 3.4.2. Porter's Five Forces Analysis

Chapter 4. U.S. Forensic Genomics Market: Product Business Analysis

• 4.1. Product Segment Dashboard
• 4.2. U.S. Forensic Genomics Market: Product Movement Analysis
• 4.3. U.S. Forensic Genomics Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
• 4.4. Analyzers & Sequencers
  • 4.4.1. Analyzers & Sequencers Market, 2021 - 2033 (USD Million)
• 4.5. Software
  • 4.5.1. Software Market, 2021 - 2033 (USD Million)
• 4.6. Kits & Consumables
  • 4.6.1. Kits & Consumables Market, 2021 - 2033 (USD Million)

Chapter 5. U.S. Forensic Genomics Market: Method Business Analysis

• 5.1. Method Segment Dashboard
• 5.2. U.S. Forensic Genomics Market: Method Movement Analysis
• 5.3. U.S. Forensic Genomics Market Size & Trend Analysis, by Method, 2021 to 2033 (USD Million)
• 5.4. Capillary Electrophoresis
  • 5.4.1. Capillary Electrophoresis Market, 2021 - 2033 (USD Million)
• 5.5. Next-generation Sequencing
  • 5.5.1. Next-generation Sequencing Market, 2021 - 2033 (USD Million)
• 5.6. PCR Amplification
  • 5.6.1. PCR Amplification Market, 2021 - 2033 (USD Million)
• 5.7. Others
  • 5.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. U.S. Forensic Genomics Market: Application Business Analysis

• 6.1. Application Segment Dashboard
• 6.2. U.S. Forensic Genomics Market: Application Movement Analysis
• 6.3. U.S. Forensic Genomics Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 6.4. Criminal Testing
  • 6.4.1. Criminal Testing Market, 2021 - 2033 (USD Million)
• 6.5. Paternity & Familial Testing
  • 6.5.1. Paternity & Familial Testing Market, 2021 - 2033 (USD Million)
• 6.6. Others
  • 6.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Participant Categorization
• 7.2. Strategy Mapping
• 7.3. Company Market Position Analysis, 2024
• 7.4. Participant's Overview
  • 7.4.1. Illumina, Inc.
    • 7.4.1.1. Overview
    • 7.4.1.2. Financial Performance
    • 7.4.1.3. Product Benchmarking
    • 7.4.1.4. Strategic Initiatives
  • 7.4.2. Thermo Fisher Scientific, Inc.
    • 7.4.2.1. Overview
    • 7.4.2.2. Financial Performance
    • 7.4.2.3. Product Benchmarking
    • 7.4.2.4. Strategic Initiatives
  • 7.4.3. Merck KGaA
    • 7.4.3.1. Overview
    • 7.4.3.2. Financial Performance
    • 7.4.3.3. Product Benchmarking
    • 7.4.3.4. Strategic Initiatives
  • 7.4.4. Agilent Technologies
    • 7.4.4.1. Overview
    • 7.4.4.2. Financial Performance
    • 7.4.4.3. Product Benchmarking
    • 7.4.4.4. Strategic Initiatives
  • 7.4.5. Promega Corporation
    • 7.4.5.1. Overview
    • 7.4.5.2. Financial Performance
    • 7.4.5.3. Product Benchmarking
    • 7.4.5.4. Strategic Initiatives
  • 7.4.6. QIAGEN
    • 7.4.6.1. Overview
    • 7.4.6.2. Financial Performance
    • 7.4.6.3. Product Benchmarking
    • 7.4.6.4. Strategic Initiatives
  • 7.4.7. Bio-Rad Laboratories
    • 7.4.7.1. Overview
    • 7.4.7.2. Financial Performance
    • 7.4.7.3. Product Benchmarking
    • 7.4.7.4. Strategic Initiatives
  • 7.4.8. LGC Limited
    • 7.4.8.1. Overview
    • 7.4.8.2. Financial Performance
    • 7.4.8.3. Product Benchmarking
    • 7.4.8.4. Strategic Initiatives
  • 7.4.9. Tri Tech Forensics
    • 7.4.9.1. Overview
    • 7.4.9.2. Financial Performance
    • 7.4.9.3. Product Benchmarking
    • 7.4.9.4. Strategic Initiatives
  • 7.4.10. Verogen
    • 7.4.10.1. Overview
    • 7.4.10.2. Financial Performance
    • 7.4.10.3. Product Benchmarking
    • 7.4.10.4. Strategic Initiatives